BI 1356 (Linagliptin) in Combination With Metformin and a Sulphonylurea in Type 2 Diabetes

PHASE3CompletedINTERVENTIONAL
Enrollment

1,058

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

May 31, 2009

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

linagliptin

active

DRUG

placebo

placebo to linagliptin 5 mg

Trial Locations (100)

Unknown

1218.18.54001 Boehringer Ingelheim Investigational Site, Capital Federal

1218.18.54002 Boehringer Ingelheim Investigational Site, Capital Federal

1218.18.54004 Boehringer Ingelheim Investigational Site, Capital Federal

1218.18.54005 Boehringer Ingelheim Investigational Site, Capital Federal

1218.18.54010 Boehringer Ingelheim Investigational Site, Capital Federal

1218.18.54014 Boehringer Ingelheim Investigational Site, Corrientes

1218.18.54009 Boehringer Ingelheim Investigational Site, Córdoba

1218.18.54013 Boehringer Ingelheim Investigational Site, Córdoba

1218.18.54003 Boehringer Ingelheim Investigational Site, Mar del Plata

1218.18.54012 Boehringer Ingelheim Investigational Site, Mar del Plata

1218.18.54011 Boehringer Ingelheim Investigational Site, Mendoza

1218.18.54015 Boehringer Ingelheim Investigational Site, Parque Velez Sarfield

1218.18.54006 Boehringer Ingelheim Investigational Site, Rosario

1218.18.54007 Boehringer Ingelheim Investigational Site, Salta

1218.18.32005 Boehringer Ingelheim Investigational Site, Bruges

1218.18.32007 Boehringer Ingelheim Investigational Site, Brussels

1218.18.32006 Boehringer Ingelheim Investigational Site, Edegem

1218.18.32004 Boehringer Ingelheim Investigational Site, Genk

1218.18.32003 Boehringer Ingelheim Investigational Site, Ghent

1218.18.32002 Boehringer Ingelheim Investigational Site, Huy

1218.18.32001 Boehringer Ingelheim Investigational Site, Liège

1218.18.01005 Boehringer Ingelheim Investigational Site, Calgary

1218.18.01010 Boehringer Ingelheim Investigational Site, Calgary

1218.18.01003 Boehringer Ingelheim Investigational Site, Vancouver

1218.18.01011 Boehringer Ingelheim Investigational Site, Vancouver

1218.18.01006 Boehringer Ingelheim Investigational Site, Etobicoke

1218.18.01009 Boehringer Ingelheim Investigational Site, Hamilton

1218.18.01002 Boehringer Ingelheim Investigational Site, London

1218.18.01012 Boehringer Ingelheim Investigational Site, Oakville

1218.18.01008 Boehringer Ingelheim Investigational Site, Sarnia

1218.18.01001 Boehringer Ingelheim Investigational Site, Toronto

1218.18.01004 Boehringer Ingelheim Investigational Site, Montague

1218.18.01007 Boehringer Ingelheim Investigational Site, Saskatoon

1218.18.86001 Boehringer Ingelheim Investigational Site, Beijing

1218.18.86002 Boehringer Ingelheim Investigational Site, Beijing

1218.18.86004 Boehringer Ingelheim Investigational Site, Beijing

1218.18.86013 Boehringer Ingelheim Investigational Site, Chengdu, Sichuan Province

1218.18.86009 Boehringer Ingelheim Investigational Site, Dalian

1218.18.86011 Boehringer Ingelheim Investigational Site, Guangzhou

1218.18.86014 Boehringer Ingelheim Investigational Site, Haerbin

1218.18.86005 Boehringer Ingelheim Investigational Site, Nanjing, Jiangsu Province

1218.18.86008 Boehringer Ingelheim Investigational Site, Qingdao

1218.18.86015 Boehringer Ingelheim Investigational Site, Shanghai

1218.18.86010 Boehringer Ingelheim Investigational Site, Shenyang

1218.18.86003 Boehringer Ingelheim Investigational Site, Weizikeng

1218.18.86007 Boehringer Ingelheim Investigational Site, Wuhan

1218.18.86012 Boehringer Ingelheim Investigational Site, Wuhan, Hubei Province

1218.18.86006 Boehringer Ingelheim Investigational Site, Xian, Shanxi Province

1218.18.49004 Boehringer Ingelheim Investigational Site, Aschaffenburg

1218.18.49028 Boehringer Ingelheim Investigational Site, Bad Mergentheim

1218.18.49022 Boehringer Ingelheim Investigational Site, Berlin

1218.18.49024 Boehringer Ingelheim Investigational Site, Bosenheim

1218.18.49020 Boehringer Ingelheim Investigational Site, Dresden

1218.18.49101 Boehringer Ingelheim Investigational Site, Mainz

1218.18.49003 Boehringer Ingelheim Investigational Site, Neuwied

1218.18.49007 Boehringer Ingelheim Investigational Site, Nuremberg

1218.18.49014 Boehringer Ingelheim Investigational Site, Saarbrücken

1218.18.63005 Boehringer Ingelheim Investigational Site, Manila

1218.18.63002 Boehringer Ingelheim Investigational Site, Marikina City

1218.18.63001 Boehringer Ingelheim Investigational Site, Pasig

1218.18.63004 Boehringer Ingelheim Investigational Site, Quezon City

1218.18.63003 Boehringer Ingelheim Investigational Site, San Juan City

1218.18.70014 Boehringer Ingelheim Investigational Site, Arkhangelsk

1218.18.70012 Boehringer Ingelheim Investigational Site, Moscow

1218.18.70013 Boehringer Ingelheim Investigational Site, Rostov-on-Don

1218.18.70015 Boehringer Ingelheim Investigational Site, Saint Petersburg

1218.18.70016 Boehringer Ingelheim Investigational Site, Samara

1218.18.82004 Boehringer Ingelheim Investigational Site, Busan

1218.18.82011 Boehringer Ingelheim Investigational Site, Daegu

1218.18.82008 Boehringer Ingelheim Investigational Site, Incheon

1218.18.82010 Boehringer Ingelheim Investigational Site, Jeonju

1218.18.82002 Boehringer Ingelheim Investigational Site, Pusan

1218.18.82001 Boehringer Ingelheim Investigational Site, Seoul

1218.18.82005 Boehringer Ingelheim Investigational Site, Seoul

1218.18.82006 Boehringer Ingelheim Investigational Site, Seoul

1218.18.82007 Boehringer Ingelheim Investigational Site, Seoul

1218.18.82009 Boehringer Ingelheim Investigational Site, Seoul

1218.18.82003 Boehringer Ingelheim Investigational Site, Suwon

1218.18.88605 Boehringer Ingelheim Investigational Site, Changhua

1218.18.88604 Boehringer Ingelheim Investigational Site, Taichung

1218.18.88606 Boehringer Ingelheim Investigational Site, Tainan City

1218.18.88601 Boehringer Ingelheim Investigational Site, Taipei

1218.18.88602 Boehringer Ingelheim Investigational Site, Taipei

1218.18.88603 Boehringer Ingelheim Investigational Site, Taipei

1218.18.88607 Boehringer Ingelheim Investigational Site, Taipei

1218.18.88608 Boehringer Ingelheim Investigational Site, Taoyuan District

1218.18.90003 Boehringer Ingelheim Investigational Site, Erzurum

1218.18.90005 Boehringer Ingelheim Investigational Site, Istanbul

1218.18.90001 Boehringer Ingelheim Investigational Site, Izmir

1218.18.90004 Boehringer Ingelheim Investigational Site, Konya

1218.18.44005 Boehringer Ingelheim Investigational Site, Ashford

1218.18.44004 Boehringer Ingelheim Investigational Site, Baillieston, Glasgow

1218.18.44001 Boehringer Ingelheim Investigational Site, Bath

1218.18.44003 Boehringer Ingelheim Investigational Site, Burbage

1218.18.44010 Boehringer Ingelheim Investigational Site, Bury Saint Edmonds

1218.18.44009 Boehringer Ingelheim Investigational Site, Cardiff

1218.18.44008 Boehringer Ingelheim Investigational Site, Glasgow

1218.18.44002 Boehringer Ingelheim Investigational Site, Penarth

1218.18.44006 Boehringer Ingelheim Investigational Site, Reading

1218.18.44007 Boehringer Ingelheim Investigational Site, Waterloo, Liverpool

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT00602472 - BI 1356 (Linagliptin) in Combination With Metformin and a Sulphonylurea in Type 2 Diabetes | Biotech Hunter | Biotech Hunter